INTELLIA THERAPEUTICS INC (NTLA)
US45826J1051 - Common Stock
INTELLIA THERAPEUTICS INC
NASDAQ:NTLA (12/20/2024, 8:00:01 PM)
After market: 12.4458 +0.27 (+2.18%)12.18
+0.1 (+0.83%)
Company Profile
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 526 full-time employees. The company went IPO on 2016-05-06. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. The company is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. The company is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Company Info
INTELLIA THERAPEUTICS INC
40 Erie St Ste 130
Cambridge MASSACHUSETTS 02139
P: 18572856200
CEO: John M. Leonard
Employees: 526
Website: https://www.intelliatx.com/
NTLA News
21 hours ago - Market News VideoFirst Week of February 2025 Options Trading For Intellia Therapeutics (NTLA)18 days ago - Intellia Therapeutics, Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
a month ago - Intellia Therapeutics, Inc.Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathyCAMBRIDGE, Mass, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
a month ago - The Motley FoolDown 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?a month ago - Intellia Therapeutics, Inc.Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisConsistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of...
a month ago - Intellia Therapeutics, Inc.Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressReceived IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin...
NTLA Twits
Here you can normally see the latest stock twits on NTLA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
